OncoSec Medical (ONCS) Gets a Buy Rating from Maxim Group

By Ryan Adsit

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on OncoSec Medical (ONCSResearch Report), with a price target of $5. The company’s shares opened today at $0.79, close to its 52-week low of $0.68.

McCarthy wrote:

“OncoSec announced the first early data from the ongoing KEYNOTE-695 study of TAVO (DNA-based IL-12) + Keytruda in metastatic melanoma patients that have failed/progressed on checkpoint therapies. Shares are down sharply (>50%), the question is why? There are several points to focus on.”

According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 6.7% and a 42.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.

OncoSec Medical has an analyst consensus of Moderate Buy, with a price target consensus of $4.50, a 472.5% upside from current levels. In a report issued on October 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $4 price target.


See today’s analyst top recommended stocks >>

The company has a one-year high of $2.95 and a one-year low of $0.68. Currently, OncoSec Medical has an average volume of 1.31M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.